面对前列腺癌这一男性泌尿系统高发肿瘤，传统雄激素剥夺治疗 (ADT)虽是基石，但"大多数患者在接受ADT后约1年内进展为去势抵抗性前列腺癌" [1]。近年来，新型内分泌治疗药物的问世为临床带来革命性突破，显著延长患者生存期并改善生活质量。

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. For American men, prostate cancer is the most common cancer ...

University Hospitals Seidman Cancer Center researchers have developed a tool that could identify metastatic prostate cancer ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Bi opsy of the P rostate A voidance S ...

The Urology Care Foundation and the Prostate Cancer Foundation have created a new educational guide on genetic tests to guide ...

A life-extending prostate cancer drug is to be made available to thousands of men in England in a matter of weeks, after a ...

Editor's note: Dr. Jamin Brahmbhatt is a urologist and robotic surgeon with Orlando Health and an assistant professor at the University of Central Florida’s College of Medicine.When I learned that ...

“For localised prostate cancer, treatment options include surgery or radiotherapy. Both give equivalent cure rates,” Dr Komen ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...

A research team from the Department of Surgery and the Department of Medicine, School of Clinical Medicine, LKS Faculty of ...

Cancer survival in the U.S. has climbed to 70%, reflecting major advances in treatment, early detection and personalized care ...